Navigation Links
ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Date:9/6/2007

LEUVEN, Belgium and LUND, Sweden, September 7 /PRNewswire/ --

- Decision Taken to Advance Novel, Long-Acting Anticoagulant Into Phase II Clinical Development

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, and co-development partner, BioInvent International (Nordic Exchange: BINV), announce today that they have successfully completed enrollment and initial follow-up of all volunteers in the first Phase I trial of TB-402, which is being developed for the prevention of venous thromboembolic disorders (VTE - blood clots).

TB-402 is a recombinant human monoclonal antibody that targets factor VIII, a component of the coagulation cascade. This antibody is a promising novel anticoagulant agent particularly because it only partially inhibits factor VIII activity even when administrated in very high doses. This may potentially decrease the risk of undesirable bleedings and the need for monitoring, which are the main concerns associated with anticoagulants currently on the market.

The trial, performed in Denmark, was a randomized, single-dose, placebo-controlled, dose-escalation trial in healthy male volunteers. 56 volunteers were enrolled into the trial, including both younger age volunteers (18-45) and older age volunteers (55-76).

Preliminary results of the trial showed that TB-402 met both the primary (safety and tolerability) and secondary (pharmacokinetic and pharmacodynamic) endpoints. The drug was well tolerated and the study showed that TB-402's prolonged half-life will allow for single-dose treatment in orthopaedic surgery patients and/or once-a-month administration for long-term stroke prevention in atrial fibrillation (AF), as opposed to daily treatment with current anticoagulants. Importantly, the findings confirm that TB-402 achieves only partial inhibition of factor VIII activity without the undesired effect of total factor VIII inactivation. Final data analysis of the first Ph
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle, WARF announce partnership to lure stem cell companies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... BOSTON, Nov. 25 Biotech firm Repl...omic data from the 1918 pandemic through the predi...pandemic, today issued its latest biochemical anal...hality of the H1N1 ("Swine Flu") virus has dropped...s current outbreak in the spring of 2009 to restin...
(Date:11/25/2009)... NEW YORK, Nov. 25 Reportlinker.co...vailable in its catalogue: ,, Brazil Bioethano...tp://www.reportlinker.com/p0165503/Brazil-Bioethan..., Brazil Bioethanol Market Analysis and Forecasts... detailed analysis and forecasts of the global bio...
(Date:11/24/2009)... The New York investment bank KTA Capital,...agreed an AU$6.7 mil convertible note private plac...ate placement was arranged by KTA Capital as Neure... New York (PRWEB) November 23, ...TA Capital, LLC ("KTA Capital") has anno...
(Date:11/24/2009)... Health care employment grew by 29,000 j... to show consistent growth during the U.S. recessi...n in trouble, and health systems are coming closer...ead of just administrators. , ...oyment continued growing in October despite the sh...
Breaking Biology Technology:Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... increasing demand for technical employees, accord...esources firm Adecco . , ,In Adecco,s "Where the ...state unemployment reports, the company states tha... a growth in technical positions in the manufactur... , ,Scott Zorn, Adecco Technical area vice pres...
...veloped at the USDA Forest Products Laboratory in ...s been acquired by Xethanol Corp. of New York. ,...s a wholly owned subsidiary of UTEK Corp., with ...Corp. is a biotechnology-driven ethanol production... stock-for-stock exchange. , ,XTI holds a license ...
...ry is becoming more and more intriguing to me. In ... of these key markets and the leading players (par...y research was the diagnostics market, I decided t...d. , ,To put diagnostics into perspective, Steve B...r of biotech trends, believes that the growth of t...
Other Biology Technology:Wisconsin's tech employment shows increase, HR firm reports 2Midwest holds strong position in worldwide diagnostics business 2Midwest holds strong position in worldwide diagnostics business 3
(Date:11/25/2009)...e California Institute of Technology (Caltech) hav...ehavior in the fruit fly, Drosophila melanogaster...e relationship between the neurotransmitter dopami...DHD), are described in the December issue of the j...ns only about 20,000 neurons and has long been con...
(Date:11/25/2009)... Cell Death Research Laboratory in the University ... the prestigious Johnson & Johnson Focused Funding...in cell damage in Parkinson,s disease. The award, ...t of innovation and excellence in science, was ann...his month at an event at the Hyatt Regency Hotel i...
(Date:11/25/2009)...e just as vital to your health as what you eat, fo...al Studies. Their experiments in mice revealed tha...s in the liverthe body,s metabolic clearinghouseis...ody,s circadian clock as conventional wisdom had i...f a large number of genes completely independent o...
Breaking Biology News(10 mins):Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 2Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 3Caltech scientists find emotion-like behaviors, regulated by dopamine, in fruit flies 4Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Feeding the clock 2Feeding the clock 3Research network based at University of Toronto gets 245 million boost to speed up cancer detection 10104 1Research network based at University of Toronto gets 245 million boost to speed up cancer detection 10104 2Detroit Clinic Owner and Manager Plead Guilty to Medicare Fraud Charges 58316 1Detroit Clinic Owner and Manager Plead Guilty to Medicare Fraud Charges 58316 2Detroit Clinic Owner and Manager Plead Guilty to Medicare Fraud Charges 58316 3Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 1Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 2Red Cross Lending a Hand to Flood Victims Unable to Go Home 58312 3
...nitiative to speed development of new medical prod...Food and Drug Administration (FDA) today issued a ...sions." , Pharmacogenomics allows health care prov...le of drug response and predict the best possible ... genomic tests are helping to identify cancers tha...
...e Scripps Research Institute is reporting a discov...ental to everything from the normal processes that...errant mechanisms that underlie many diseases, inc...oncerns tiny fragments of RNA known as microRNA an...own as messenger RNA (mRNA). , All genes expresse...
... has been discovered by a team of researchers at P...works with another tumor suppressor to control tis...dies will be published in the 11 March 2005 issue ...nderstanding of how tissue growth is controlled bo...ion of tumors, and it raises the possibility that ...
Other Biology News:FDA Works To Speed The Advent Of New, More Effective Personalized Medicines 2FDA Works To Speed The Advent Of New, More Effective Personalized Medicines 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 2Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 3Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression 4New tumor-suppressor gene discovered 2New tumor-suppressor gene discovered 3New tumor-suppressor gene discovered 4
...t and effectively in tubes and 96 well plates. mic..., one and a half spin DNA cleanup reagent. It can ...ble stranded DNA, efficiently removing reaction bu...abelled or unlabelled). It is therefore ideally su...
SUPER SENSITIVE READY-TO-USE MULTILINK IHC DETECTION KIT, HORSE RADISH PEROXIDASE/AEC, FOR AUTOMATION from BioGenex
...Deparaffinization Solution is available in a ready...gent for dewaxing paraffin-embedded tissue section...u hybridization, or other analytical methods. The ...f dipping the slides in a series of baths of xylen...
Artisan™ Wash Solution (x 50) from Dako
Biology Products: